Health and Healthcare
Was the Immunomedics Sell-Off Too Extreme?
Published:
Last Updated:
Source: Thinkstock
For some background, UCB had licensed epratuzumab from Immunomedics to treat lupus, an autoimmune disease where the body’s immune system attacks healthy organs; it affects 5 million people around the world.
So far, epratuzumab is only an investigational medicine and is not approved for the treatment of SLE by any regulatory authority worldwide. It is a monoclonal antibody to target CD22, a protein that modulates B-cells, key components of the immune system that can play a central role in the pathogenesis of SLE if they become overactive.
Professor Dr. Iris Loew-Friedrich, Chief Medical Officer and Executive Vice President of UCB, commented on the failed trial:
Although we are disappointed with the results from the Phase 3 program, our commitment to the lupus community remains. We are focused on developing new therapies for the treatment of immunological conditions including SLE and have another SLE drug in clinical development. We would like to express our sincere thanks to the patients and clinical investigators who made the EMBODY program possible. It has produced a comprehensive dataset and we look forward to sharing the findings with the scientific community. Today’s news does not alter UCB’s strategy as we remain committed to delivering value for patients living with lupus and other immunologic diseases.
The question on investors’ minds now is that: if UCB can’t get Epratuzumab off the ground does Immunomedics stand a chance of doing so as well?
Shares of Immunomedics were down 34.2% at $2.44 on Tuesday morning. The stock has a consensus analyst price target of $7.00 and a 52-week trading range of $1.83 to $5.48. It’s worth noting that shares have not traded this low since 2009.
Take This Retirement Quiz To Get Matched With A Financial Advisor (Sponsored)
Take the quiz below to get matched with a financial advisor today.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Take the retirement quiz right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
